Novartis Ligelizumab (QGE031) treats Patients with CSU with higher remission rates

CSU is a severe skin disease with unpredictable seizures, symptoms including spontaneous swelling and itching of the skinNovartis(http://announced that the company's development of anti-IgE humanized monoclonal antibody ligelizumab (QGE031) has completely alleviated the symptoms of more patients in a 2b-phasetest (http://for chronic spontaneous urticaria (CSU) patients with poor control of H1-antihistamineAbout Ligelizumab
Ligelizumab is a monoclonal antibody acting on IgE (Immunoglobulin E) antibodies and is currently in the clinical development stage for the treatment of Patients with CSU with poor Control of H1-antihistaminesXolair is currently the only recommended treatment for Patients with CSU with poor control of antihistaminesIn a randomized, double-blind, active-controlled Phase 2b clinical trial, 382 Patients with H1-antihistaminedrug(http://were randomly treated with three different doses of ligelizumab or Xolair in poorly controlled CSU patientsInterim data from the trial showed that in the 12th week of treatment, 30% (24 mg in dose), 44% (72 mg) and 40% (240 mg) of patients receiving ligelizumab were completely relievedIn the Xolair treatment group, the figure was 26%